Pertussis (ICD-11: 1C12) - Complete Clinical Coding Guide

1. Introduction

Pertussis is an acute bacterial infection of the respiratory tract caused by the bacterium Bordetella pertussis, characterized by paroxysmal attacks of intense cough followed by a characteristic sharp inspiratory sound, known as a "whoop". This highly contagious disease represents a significant challenge for global public health, despite the availability of effective vaccines for decades.

The clinical importance of pertussis lies in its potential severity, especially in infants under six months of age, who present a higher risk of serious complications such as pneumonia, seizures, encephalopathy, and death. In older children and adults, although generally less severe, the disease can cause significant morbidity with persistent cough that can last weeks or months, justifying its historical nickname of "100-day cough".

In recent decades, there has been a resurgence of pertussis in various regions, even in areas with high vaccination coverage rates. This phenomenon has been attributed to multiple factors, including diminished immunity over time, changes in circulating bacterial strains, and greater diagnostic recognition in adolescents and adults.

Correct coding of pertussis is critical for epidemiological surveillance, allowing monitoring of outbreaks, evaluation of vaccination program effectiveness, and appropriate allocation of public health resources. Furthermore, accurate documentation ensures appropriate reimbursement for services rendered and facilitates research on disease patterns and prevention strategies.

2. Correct ICD-11 Code

Code: 1C12

Description: Pertussis

Parent category: null - Other bacterial diseases

Official definition: Acute bacterial infection of the respiratory tract caused by Bordetella pertussis.

This specific code in ICD-11 unequivocally identifies infection caused by Bordetella pertussis, distinguishing it from other bacterial respiratory infections and pertussis-like syndromes caused by other pathogens. The classification under "Other bacterial diseases" reflects its nature as a specific bacterial infection with distinct clinical characteristics.

Code 1C12 should be used when there is laboratory confirmation of Bordetella pertussis infection or when clinical criteria are sufficiently characteristic to establish the diagnosis based on epidemiological and clinical grounds. The specificity of this code allows for precise epidemiological tracking and differentiation from other causes of prolonged or paroxysmal cough.

3. When to Use This Code

Code 1C12 should be applied in specific clinical situations where there is evidence of infection by Bordetella pertussis:

Scenario 1: Infant with laboratory-confirmed paroxysmal cough A 3-month-old child presents with cough for two weeks, initially mild, but progressing to intense coughing fits followed by vomiting. Parents report that during the fits the child becomes flushed and presents with respiratory difficulty. PCR for Bordetella pertussis was performed with a positive result. This is the classic scenario for use of code 1C12.

Scenario 2: Unvaccinated child with characteristic clinical presentation A 2-year-old patient with no history of complete vaccination develops progressive cough over three weeks. In the current phase, presents with violent coughing fits followed by the characteristic inspiratory whoop, with leukocytosis and absolute lymphocytosis. Even without laboratory confirmation, the typical clinical presentation in an appropriate epidemiological context justifies code 1C12.

Scenario 3: Adolescent with persistent cough and confirmed contact A 15-year-old adolescent presents with persistent cough for four weeks, without fever, but with coughing fits that provoke vomiting. Had close contact with younger sibling diagnosed with pertussis. Nasopharyngeal culture confirms Bordetella pertussis. Code 1C12 is appropriate regardless of the patient's age.

Scenario 4: Adult with confirmed pertussis-like syndrome A 35-year-old adult, healthcare professional, develops initially dry cough that evolves to paroxysmal fits over three weeks. Reports contact with pediatric patient subsequently diagnosed with pertussis. Positive PCR for Bordetella pertussis confirms the diagnosis, justifying code 1C12.

Scenario 5: Outbreak in institution with multiple confirmed cases During investigation of an outbreak in an educational institution, several individuals develop prolonged cough with similar characteristics. Index cases have laboratory confirmation of Bordetella pertussis. Subsequent cases with compatible clinical presentation and clear epidemiological link may be coded as 1C12.

Scenario 6: Newborn with apnea and diagnostic confirmation A 6-week-old infant hospitalized for episodes of apnea and cyanosis, with minimal or absent cough. Laboratory investigation reveals infection by Bordetella pertussis. Even without the classic presentation of paroxysmal cough, laboratory confirmation in a young infant with compatible manifestations justifies code 1C12.

4. When NOT to Use This Code

Code 1C12 should not be used in various situations that may be confused with pertussis:

Pertussis-like syndrome from other pathogens: When paroxysmal cough is caused by other agents such as Bordetella parapertussis, adenovirus, respiratory syncytial virus, or Mycoplasma pneumoniae, different codes should be used. Laboratory confirmation is essential for this differentiation.

Chronic cough from other etiologies: Patients with asthma, gastroesophageal reflux, postnasal drip, or other causes of prolonged cough should not receive code 1C12, even if the cough is intense or paroxysmal, if there is no evidence of Bordetella pertussis infection.

Acute or chronic bronchitis: Common bacterial or viral respiratory infections that cause cough, even when prolonged, should not be coded as pertussis without specific evidence of Bordetella pertussis.

Asymptomatic carrier state: Individuals with positive culture or PCR for Bordetella pertussis but without clinical symptoms represent a special situation that may require different coding, depending on the clinical context and purpose of documentation.

Vaccine reaction: Temporary respiratory symptoms following pertussis vaccination should not be coded as pertussis, but rather as an adverse vaccine reaction, with the appropriate code for adverse events.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

The diagnosis of pertussis requires careful evaluation of clinical and laboratory criteria. Clinically, the disease classically evolves in three phases: catarrhal (1-2 weeks with nonspecific cold-like symptoms), paroxysmal (2-6 weeks with characteristic cough), and convalescence (weeks to months with gradual improvement).

Clinical criteria include cough lasting at least two weeks with at least one of the following characteristics: paroxysmal coughing fits, characteristic inspiratory whoop, post-cough vomiting without other apparent cause, or apnea in infants. In young infants, the presentation may be atypical, with apnea, cyanosis, or feeding difficulty predominating over cough.

Laboratory confirmation is preferably performed by nasopharyngeal secretion culture (gold standard, but less sensitive after three weeks of illness) or PCR (more sensitive, especially in the first four weeks). Serology may be useful in late cases or for retrospective diagnosis. Suggestive laboratory findings include leukocytosis with absolute lymphocytosis, particularly in young children.

Step 2: Check Specifiers

Pertussis can vary in severity from mild cases with minimal cough to severe disease with complications. Although code 1C12 does not have mandatory subcategories for severity, documentation should include:

Severity: Mild (cough without significant impact), moderate (cough interfering with daily activities), severe (requiring hospitalization, with complications such as apnea, secondary pneumonia, seizures).

Phase of illness: Catarrhal, paroxysmal, or convalescence, which may influence therapeutic decisions and prognosis.

Complications: Secondary pneumonia, otitis media, weight loss, hernias, rib fractures (from intense coughing), encephalopathy, seizures, or death (rare, but possible in infants).

Vaccination status: Documenting vaccination history is essential for clinical and epidemiological context.

Step 3: Differentiate from Other Codes

1C10 - Actinomycosis: Chronic bacterial infection caused by Actinomyces spp., characterized by abscesses and fistula formation, typically cervicofacial, thoracic, or abdominal. It differs from pertussis by not primarily causing acute respiratory symptoms or paroxysmal cough, but rather chronic suppurative lesions.

1C11 - Bartonellosis: Infection caused by Bartonella bacilliformis, transmitted by vectors, with two main presentations: Oroya fever (acute hemolytic anemia) and Peruvian wart (cutaneous lesions). It does not present with paroxysmal cough and has epidemiology and clinical manifestations completely distinct from pertussis.

1C13 - Tetanus: Infection caused by Clostridium tetani, characterized by muscle spasms and rigidity due to tetanic neurotoxin. It manifests with trismus, neck rigidity, opisthotonus, and generalized muscle spasms, without primary respiratory symptoms or cough, clearly differentiating it from pertussis.

Step 4: Required Documentation

For appropriate coding with 1C12, medical documentation must include:

Mandatory checklist:

Detailed description of cough (duration, characteristics, presence of paroxysms)
Presence or absence of inspiratory whoop
Associated symptoms (post-cough vomiting, apnea, cyanosis)
History of exposure or sick contacts
Complete vaccination status of the patient
Laboratory test results (PCR, culture, serology)
Phase of illness at the time of evaluation
Presence of complications
Treatment instituted

Adequate record: Documentation should allow another professional, upon reviewing the medical record, to clearly understand why the diagnosis of pertussis was established and how it was confirmed, whether by clinical criteria, laboratory criteria, or both.

6. Complete Practical Example

Clinical Case

A 4-month-old female patient is brought to the emergency department by her parents with a complaint of cough for 10 days and episodes of "stopping breathing" in the last 48 hours. The mother reports that initially the child presented with clear rhinorrhea and mild cough, without fever. After one week, the cough intensified, occurring in violent paroxysms, during which the child turns red and has difficulty breathing. After the paroxysms, she frequently vomits. In the last two days, the parents noticed episodes in which the child stops breathing for a few seconds, becoming cyanotic.

Past medical history reveals that the patient received only the first dose of pertussis vaccine at 2 months of age. The 8-year-old sibling had "severe cough" three weeks ago, treated on an outpatient basis, but without a specific diagnosis established. The child has attended daycare since 3 months of age.

On physical examination: infant in fair general condition, irritable, respiratory rate of 45 breaths per minute, oxygen saturation 94% on room air, afebrile. During evaluation, she presents with a paroxysmal cough crisis followed by inspiratory whoop and vomiting. Pulmonary auscultation without adventitious sounds between crises. Cardiovascular and abdominal examination unremarkable.

Complementary tests ordered: complete blood count revealed leukocytosis (28,000/mm³) with absolute lymphocytosis (18,000/mm³). Chest X-ray without infiltrates. Nasopharyngeal secretion collection for PCR of Bordetella pertussis was performed.

The patient was hospitalized for continuous cardiorespiratory monitoring due to apnea episodes. Treatment with azithromycin was initiated. PCR returned positive for Bordetella pertussis 48 hours after collection. Family members and close contacts were counseled regarding antibiotic prophylaxis.

Coding Step by Step

Criteria Analysis:

Clinical criteria present: Cough lasting more than one week, paroxysmal cough crises, characteristic inspiratory whoop, post-cough vomiting, apnea episodes (typical manifestation in young infants).
Epidemiological context: Incompletely vaccinated infant, household contact with recent respiratory illness, attendance in collective environment (daycare).
Suggestive laboratory findings: Leukocytosis with absolute lymphocytosis, characteristic pattern in infants with pertussis.
Laboratory confirmation: Positive PCR for Bordetella pertussis, definitively confirming the diagnosis.

Code Selected: 1C12 - Pertussis

Complete Justification:

Code 1C12 is appropriate for this case because there is definitive laboratory confirmation of Bordetella pertussis infection through PCR, associated with a characteristic clinical presentation of pertussis in the paroxysmal phase. The clinical presentation is typical for the age group, including paroxysmal cough, inspiratory whoop, and apnea. The epidemiological context (sick household contact, incomplete vaccination) and laboratory findings (leukocytosis with lymphocytosis) corroborate the diagnosis.

Complementary Codes:

Depending on the coding system and documentation needs, codes may be added for:

Apnea as a complication (if specific code is available)
Incomplete vaccination status (if relevant for epidemiological record)
Need for respiratory isolation (for hospital administrative purposes)

7. Related Codes and Differentiation

Within the Same Category

1C10 - Actinomycosis: Actinomycosis is a chronic bacterial infection caused by Actinomyces species, gram-positive anaerobic bacteria that are part of the normal flora of the mouth and gastrointestinal tract. Use 1C10 when the patient presents with chronic abscesses, fistulas with drainage of sulfur granules, typically in the cervicofacial, thoracic, or abdominal region. The main difference from 1C12 is that actinomycosis does not cause acute respiratory symptoms or paroxysmal cough, but rather chronic suppurative processes with mass formation and fistulas.

1C11 - Bartonellosis: Bartonellosis is caused by Bartonella bacilliformis, transmitted by phlebotomine sand flies in specific regions. Use 1C11 when there are manifestations of Oroya fever (severe hemolytic anemia, fever, lymphadenopathy) or Peruvian wart (nodular vascular cutaneous lesions). The fundamental difference from 1C12 is the absence of respiratory symptoms, vector transmission, and characteristic systemic or dermatological manifestations, completely distinct from pertussis.

1C13 - Tetanus: Tetanus is caused by the neurotoxin produced by Clostridium tetani, usually after contaminated wounds. Use 1C13 when there are muscle spasms, generalized rigidity, trismus, dysphagia, and opisthotonus. The main difference from 1C12 is that tetanus is a neuromuscular disease without primary respiratory involvement (although there may be respiratory compromise secondary to spasms), without cough and with characteristic neuromuscular clinical presentation.

Differential Diagnoses

Viral bronchiolitis: Common in infants, caused mainly by respiratory syncytial virus, characterized by wheezing, tachypnea, and retractions, differentiated by the absence of typical paroxysmal cough and inspiratory stridor.

Asthma: Can cause paroxysmal cough, especially nocturnal, but generally associated with wheezing, response to bronchodilators, and history of atopy, without the characteristic evolutionary pattern of pertussis.

Foreign body in airway: Can cause sudden and persistent cough, but usually with abrupt onset following an aspiration event, without the progressive evolution of pertussis.

Mycoplasma pneumoniae infection: Can cause prolonged cough, but generally without the characteristic paroxysmal pattern, with different radiological findings and response to specific antibiotics.

8. Differences with ICD-10

In ICD-10, pertussis was coded as A37, with subdivisions:

A37.0: Pertussis due to Bordetella pertussis
A37.1: Pertussis due to Bordetella parapertussis
A37.8: Pertussis due to other species of Bordetella
A37.9: Pertussis, unspecified

The main change in ICD-11 with code 1C12 is the simplification of the structure, with specific focus on infection by Bordetella pertussis. ICD-11 offers greater clarity by specifically defining pertussis as infection by B. pertussis, while infections by other agents that cause similar syndromes can be classified separately.

The practical impact of these changes includes greater precision in epidemiological surveillance, allowing more specific tracking of true pertussis caused by B. pertussis, separating it from pertussis-like syndromes caused by other pathogens. This facilitates the evaluation of vaccination program effectiveness and monitoring of resistance patterns and changes in circulating strains.

For professionals accustomed to ICD-10, the transition requires attention to avoid confusing code 1C12 (specific for B. pertussis) with cases caused by other agents, which previously could be included under A37.8 or A37.9.

9. Frequently Asked Questions

How is pertussis diagnosed?

The diagnosis combines clinical evaluation and laboratory confirmation. Clinically, a history of cough for at least two weeks with paroxysmal characteristics, inspiratory whoop, post-cough vomiting, or apnea in infants is sought. The preferred laboratory confirmation is by PCR of nasopharyngeal secretion within the first four weeks of symptoms, or culture (gold standard, but less sensitive). Serology can be useful after three weeks of illness. In epidemic contexts, clinical diagnosis with epidemiological linkage may be sufficient.

Is treatment available in public health systems?

Yes, antibiotic treatment for pertussis is generally available in public health systems. The antibiotics of choice are macrolides (azithromycin, clarithromycin, or erythromycin), medications widely available and included in essential medicine lists. Treatment is most effective when started in the catarrhal phase or early paroxysmal phase, reducing transmission, although it has limited impact on symptom duration if started late.

How long does treatment last?

Typical antibiotic treatment lasts 5 days with azithromycin (1 daily dose) or 7 days with clarithromycin (2 daily doses), or 14 days with erythromycin (4 daily doses). Although antibiotic treatment eliminates the bacteria and reduces transmission, cough symptoms may persist for weeks or months, as airway damage has already occurred. Supportive treatment, including hydration, adequate nutrition, and monitoring in severe cases, continues throughout the symptomatic period.

Can this code be used on medical certificates?

Yes, code 1C12 can and should be used on medical certificates when appropriate. Pertussis justifies absence from work or school activities due to the highly contagious nature of the disease and severity of symptoms. The recommended period of absence is generally 5 days after initiation of appropriate antibiotic treatment, or 21 days from the onset of paroxysmal cough if untreated. Proper documentation with the correct code is essential to justify the absence.

Can vaccinated adults develop pertussis?

Yes, adults can develop pertussis even with a history of childhood vaccination. The immunity conferred by the vaccine decreases over time, making adolescents and adults susceptible to infection. In adults, the presentation may be atypical, with prolonged cough without the characteristic whoop, often misdiagnosed as bronchitis. Adults are an important source of transmission to unimmunized infants, justifying booster vaccination strategies.

What are the most serious complications of pertussis?

The most serious complications occur mainly in infants under 6 months of age. They include secondary pneumonia (the most common complication), apnea with risk of cerebral hypoxia, seizures, encephalopathy, malnutrition, and dehydration due to frequent vomiting. Mechanical complications from intense coughing include subconjunctival hemorrhages, hernias, pneumothorax, and rarely, rib fractures. Mortality, although rare in countries with good health resources, occurs almost exclusively in young infants.

How to prevent pertussis?

Primary prevention is through vaccination. Vaccination schedules include doses in childhood (typically at 2, 4, and 6 months, with subsequent boosters) and booster doses in adolescents and adults. Pregnant women should receive a booster dose during each pregnancy to transfer protective antibodies to the newborn. Post-exposure prophylaxis with antibiotics is recommended for close contacts of confirmed cases, especially if there are unimmunized infants in the environment. Respiratory isolation of confirmed cases reduces transmission.

When does a patient with pertussis stop being contagious?

A patient with pertussis is highly contagious from the beginning of the catarrhal phase until approximately three weeks after the onset of paroxysmal cough, if untreated. With appropriate antibiotic treatment, the contagious period is reduced to approximately 5 days after initiation of treatment. Therefore, respiratory isolation and absence from activities are recommended until completing 5 days of antibiotic therapy or, if untreated, for 21 days from the onset of paroxysms. Contacts should be monitored and may receive antibiotic prophylaxis.

Keywords: ICD-11 1C12, pertussis, Bordetella pertussis, paroxysmal cough, inspiratory whoop, medical coding, pertussis diagnosis, vaccination, whooping cough, bacterial respiratory infection.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-03

Whooping Cough

Share